DPP4 and chronic kidney disease: In fact, DPP-4 has the highest expression levels in the kidneys of mammals, which is additionally upregulated in diabetic-induced CKD, indicating that DPP-4 inhibition by sitagliptin is a plausible therapeutic target for management of DN.